Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Duration of 40U Jeuveau in Glabellar Lines
NCT05320393Phase 2Completed
- Sponsor
- Evolus, Inc.
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of prabotulinumtoxinA in glabellar lines, sponsored by Evolus, Inc.. Started Mar 2022; status: completed.
02
Drugs
prabotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05320393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320393.